After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

PALO ALTO, CA, USA I March 17, 2025 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in ...

With the aim of overcoming these issues, researchers from Recourse Biologics Inc. designed a potentially first-in-class immunostimulatory fusion protein.

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

Because the aim of the experiment is to compare GST with a GST fusion protein, it is necessary to prepare enough precleared lysate for each reaction. Efficient mixing of reagents is the key to ...

These fusion proteins are the basis of many subunit vaccines, a type in which a part of the pathogen being vaccinated against is injected to prompt the body to efficiently raise an immune response ...

It does that by talking to the membrane fusion protein." More information: Chanwoo Lee et al, Exocyst stimulates multiple steps of exocytic SNARE complex assembly and vesicle fusion, Nature ...

Unique approach targets IL-18 with a smaller, IL-18 fusion protein antagonist, with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies EVO301 has ...